References
- Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscl Throm Vas. 2003; 23:168-75.10.1161/01.ATV.0000051384.43104.FC
- Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. J Am Coll Cardiol. 2002; 39:257-65.10.1016/S0735-1097(01)01746-611788217
- Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-26.988716410.1056/NEJM199901143400207
- Vita JA, Keaney Jr JF. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002; 106:640-2.1216341910.1161/01.CIR.0000028581.07992.56
- Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscl Throm Vas. 2003; 23:168-75.10.1161/01.ATV.0000051384.43104.FC
- Chang JA, Froelicher VF. Clinical and exercise test markers of prognosis in patients with stable coronary artery disease. Curr Probl Cardiol. 1994; 19:533-87.7813229
- Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101:1899-906.10.1161/01.CIR.101.16.189910779454
- Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101:948-54.1070415910.1161/01.CIR.101.9.948
- Anuurad E, Ozturk Z, Enkhmaa B, Pearson TA, Berglund L. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab. 2010; 95:2376-83.2019470710.1210/jc.2009-2498
- Ozturk ZG, Ekmekci H, Ekmekci OB, Atukeren P, Butun I, Gode S, el al. Nontraditional risk factors in carotid artery disease. Clin Appl Thromb Hemost. 2010; 16:554-8.10.1177/107602960935432820460338
- Gungor Z, Anuurad E, Enkhmaa B, Zhang W, Kim K, Berglund L. ApoE4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis. 2012; 223:230-4.10.1016/j.atherosclerosis.2012.04.02122632920
- Anuurad E, Tracy RP, Pearson TA, Beckett L, Berglund L. Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans. Am J Cardiol. 2009; 103:523-7.1919551410.1016/j.amjcard.2008.10.016
- Bilgen D, Sonmez H, Ekmekci H, Ulutin T, Ozturk Z, Kokoglu E, el al. The relationship of TFPI, Lp(a) and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem. 2005; 38:92-6.1560732410.1016/j.clinbiochem.2004.09.011
- Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Inter Med. 2009; 151:483-95.10.7326/0003-4819-151-7-200910060-00009
- Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Arterioscl Throm Vas. 2005; 25:923-31.10.1161/01.ATV.0000160551.21962.a7
- H kkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, el al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscl Throm Vas. 1999; 19:2909-17.10.1161/01.ATV.19.12.2909
- Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscl Throm Vas. 2006; 26:2523-9.10.1161/01.ATV.0000244681.72738.bc
- Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, Kim SE, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr. 2008; 88:630-7.18779277
- Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoproteinassociated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008; 101:51F-7.10.1016/j.amjcard.2008.04.019
- Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J. 1973; 85:546-62.463200410.1016/0002-8703(73)90502-4
- Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959; 234:1971-5.13672998
- Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994; 24:1468-74.10.1016/0735-1097(94)90141-47930277
- Celermajer DS, Sorensen KE, Georgakopoulos D. Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993; 88:2149-55.10.1161/01.CIR.88.5.21498222109
- Celermajer DS, Sorensen KE, Gaoch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340:1111-5.10.1016/0140-6736(92)93147-F1359209
- Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991; 325:849-53.10.1056/NEJM1991091932512041875969
- McNeer JF, Margolis JR, Lee KL, Kisslo JA, Peter RH, Kong Y, et al. The role of the exercise test in the evaluation of patients for ischemic heart disease. Circulation. 1978; 57:64-70.10.1161/01.CIR.57.1.64618399
- Weiner DA. The diagnostic and prognostic significance of an asymptomatic positive exercise test. Circulation. 1987; 75:II20-1.3815782
- Mark DB, Hlatky MA, Califf RM, Morris JJ Jr, Sisson SD, McCants CB, et al. Painless exercise ST deviation on the treadmill: long term prognosis. J Am Coll Cardiol. 1989; 14:885-92.10.1016/0735-1097(89)90459-22794272
- Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease. Circulation. 2003; 108:2093-8.10.1161/01.CIR.0000095273.92468.D914530195
- Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation. 2004; 109:2518-23.1513649810.1161/01.CIR.0000128208.22378.E3
- Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003; 41:1769-75.1276766310.1016/S0735-1097(03)00333-4
- Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002; 105:1567-73.1192752410.1161/01.CIR.0000012543.55874.47
- Shechter M, Issachar A, Marai I, Koren-Morag N, Freinark D, Shahar Y, et al. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol. 2009; 134: 52-8.10.1016/j.ijcard.2008.01.02118479768
- Witte DR, Broekmans WM, Kardinaal AF, Klöpping-Ketelaars IA, van Poppel G, Bots ML, et al. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis. 2003; 170:147-53.1295769310.1016/S0021-9150(03)00253-3
- Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flowmediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009; 120:502-9. 10.1161/CIRCULATIONAHA.109.864801